Table 1.
Characteristics and outcomes of patients ( mean ± SD)
|
Arterial steroid injection therapy |
||||
| Yes | No | Total | P | |
| n | 17 | 17 | 34 | |
| Sex (male/female) | 11/6 | 10/7 | 21/13 | 0.7242 |
| Age (yr) | 45.1 ± 16.9 | 44.8 ± 19.0 | 45.0 ± 17.7 | 0.9623 |
| Ascites (none/present) | 12/5 | 7/10 | 19/15 | 0.0842 |
| Encephalopathy | 5/4/3/5 | 11/0/5/1 | 16/4/8/6 | 0.0242 |
| (0/1/2/3) | ||||
| T.bilirubin (mg/dL) | 9.04 ± 9.21 | 14.48 ± 9.62 | 11.76 ± 9.67 | 0.1014 |
| D.bilirubin (mg/dL) | 6.15 ± 6.73 | 9.08 ± 6.71 | 7.61 ± 6.79 | 0.2131 |
| D/T bilirubin ratio | 0.66 ± 0.06 | 0.61 ± 0.12 | 0.64 ± 0.10 | 0.1785 |
| Albumin (g/dL) | 3.55 ± 0.46 | 3.25 ± 0.32 | 3.40 ± 0.42 | 0.0362 |
| ChE (mg/dL) | 111.7 ± 40.5 | 95.4 ± 31.3 | 103.8 ± 36.7 | 0.2047 |
| AST (U/L) | 5817.5 ± 4223.6 | 3203.71 ± 2829.2 | 4510.62 ± 3780.2 | 0.0530 |
| ALT (U/L) | 4056.7 ± 2427.3 | 3643.71 ± 2677.1 | 3850.21 ± 2525.0 | 0.6407 |
| AST/ALT ratio | 1.58 ± 1.16 | 0.99 ± 0.68 | 1.28 ± 0.98 | 0.0833 |
| ALP (U/L) | 539.5 ± 258.3 | 517.8 ± 178.0 | 528.6 ± 218.1 | 0.7775 |
| γ-GTP (U/L) | 336.4 ± 351.2 | 182.0 ± 182.0 | 261.5 ± 288.7 | 0.1228 |
| LDH (U/L) | 4349.3 ± 4479.0 | 1343.3 ± 2553.1 | 2846.3 ± 3900.6 | 0.0238 |
| PT-INR | 2.50 ± 1.60 | 2.93 ± 1.92 | 2.71 ± 1.76 | 0.4890 |
| Platelet (× 104/μL) | 13.9 ± 5.5 | 11.8 ± 4.2 | 12.8 ± 4.9 | 0.2121 |
| AFP (ng/mL) | 16.7 ± 27.2 | 29.6 ± 43.8 | 23.2 ± 36.5 | 0.3125 |
| NH3 (μg/dL) | 90.5 ± 87.0 | 63.6 ± 32.2 | 77.1 ± 66.1 | 0.2451 |
| BUN (mg/dL) | 14.1 ± 10.9 | 14.8 ± 18.6 | 14.4 ± 15.0 | 0.8850 |
| Creatinine (mg/dl) | 1.20 ± 1.30 | 1.16 ± 1.24 | 1.18 ± 1.25 | 0.9210 |
| Outcome | 13/2/2 | 4/7/6 | 17/9/8 | 0.0085 |
| (Survival/death/LT) | ||||
P-values were calculated to compare the patients treated with and without TASIT.